Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.52 |
| ▸ | HTR1A | P08908 | 3/20 | 0.45 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457335 | 0.97 | DRD2 (0.51) | DRD2HTR1ASUV39H2SIGMAR1TDP1 | |
| SCHEMBL5455064 | 0.94 | DRD2 (0.49) | DRD2HTR1ASUV39H2SIGMAR1HTR1D | |
| SCHEMBL5452326 | 0.88 | DRD2 (0.46) | DRD2HTR1ASIGMAR1HTR1DHTR1B | |
| SCHEMBL5448066 | 0.85 | DRD2 (0.54) | DRD2HTR1ADRD4 | |
| SCHEMBL5453590 | 0.85 | WDR5 (0.45) | DRD2HTR1ASIGMAR1HTR1DHTR1B | |
| SCHEMBL5448035 | 0.84 | DRD3 (0.50) | DRD2HTR1ADRD4 | |
| SCHEMBL5454904 | 0.84 | HTR1A (0.49) | DRD2HTR1ADRD4 | |
| SCHEMBL5452400 | 0.83 | HTR1A (0.51) | DRD2HTR1ASIGMAR1HTR1DHTR1B | |
| SCHEMBL5450130 | 0.82 | DRD2 (0.52) | DRD2HTR1ADRD4 | |
| SCHEMBL5458682 | 0.82 | HTR1A (0.49) | DRD2HTR1ASIGMAR1HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | DRD2 27/4885HTR1A 3/4885SUV39H2 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.